Rep. Thomas H. Kean, Jr. Sells Stryker Corporation (NYSE:SYK) Stock

Posted by Kyle Jackson on Aug 21st, 2026

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Stryker Corporation (NYSE:SYK). In a filing disclosed on August 18th, the Representative disclosed that they had sold between $1,001 and $15,000 in Stryker stock on July 22nd. The trade occurred in the Representative’s “STATE STREET BANK & TRUST CO.” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 7/22/2026.
Sold $1,001 – $15,000 in shares of Analog Devices (NASDAQ:ADI) on 6/30/2026.
Sold $1,001 – $15,000 in shares of S&P Global (NYSE:SPGI) on 6/29/2026.
Sold $1,001 – $15,000 in shares of Markel Group (NYSE:MKL) on 6/29/2026.
Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 6/29/2026.
Purchased $1,001 – $15,000 in shares of ESAB (NYSE:ESAB) on 6/24/2026.
Sold $15,001 – $50,000 in shares of Alphabet (NASDAQ:GOOGL) on 6/24/2026.
Purchased $1,001 – $15,000 in shares of ESAB (NYSE:ESAB) on 6/22/2026.
Sold $1,001 – $15,000 in shares of Gildan Activewear (NYSE:GIL) on 6/17/2026.
Purchased $1,001 – $15,000 in shares of Wheaton Precious Metals (NYSE:WPM) on 6/4/2026.

Stryker Stock Performance

NYSE:SYK opened at $327.97 on Friday. The firm has a market capitalization of $125.80 billion, a PE ratio of 33.99, a PEG ratio of 2.17 and a beta of 0.76. The stock’s fifty day moving average is $326.64 and its 200 day moving average is $332.66. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16.

Stryker (NYSE:SYK – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. During the same quarter in the previous year, the business posted $3.13 earnings per share. The business’s revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, sell-side analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio is presently 36.48%.

Wall Street Analyst Weigh In

SYK has been the subject of a number of recent analyst reports. Argus set a $370.00 target price on shares of Stryker in a research note on Thursday, July 9th. Royal Bank Of Canada decreased their price objective on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Citigroup reissued a “buy” rating on shares of Stryker in a research report on Thursday, August 13th. Canaccord Genuity Group reduced their target price on shares of Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Finally, Deutsche Bank Aktiengesellschaft set a $315.00 price target on shares of Stryker in a research note on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $386.28.

Check Out Our Latest Research Report on SYK

Insider Buying and Selling

In related news, insider Debra King sold 826 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at $2,088,423. This trade represents a 11.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 665,370 shares of company stock worth $216,238,501 in the last ninety days. 4.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Stryker

Several institutional investors have recently bought and sold shares of SYK. Banco de Sabadell S.A raised its stake in Stryker by 1.3% in the second quarter. Banco de Sabadell S.A now owns 5,843 shares of the medical technology company’s stock worth $1,848,000 after buying an additional 74 shares in the last quarter. Chesapeake Wealth Management boosted its holdings in shares of Stryker by 15.1% in the 2nd quarter. Chesapeake Wealth Management now owns 1,665 shares of the medical technology company’s stock valued at $524,000 after buying an additional 218 shares in the last quarter. Proficio Capital Partners LLC purchased a new position in shares of Stryker in the 2nd quarter worth approximately $657,000. Community Bank & Trust Waco Texas lifted its position in Stryker by 2.3% during the second quarter. Community Bank & Trust Waco Texas now owns 1,395 shares of the medical technology company’s stock valued at $439,000 after acquiring an additional 31 shares during the last quarter. Finally, Nwam LLC grew its holdings in Stryker by 51.6% in the second quarter. Nwam LLC now owns 11,963 shares of the medical technology company’s stock worth $3,767,000 after purchasing an additional 4,071 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

Stryker Company Profile

(Get Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.